Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments

14 Apr 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Weir et al. reviewed the use of surrogate endpoints in health technology assessment (HTA) processes used to evaluate drugs and biologic therapies and developed an overview of statistical methods for surrogate evaluation. In addition, the authors described how regulatory authorities, payers, and HTA agencies use clinical trial evidence based on surrogate outcomes. Despite the focus on pharmaceuticals, the article can be of interest to the audience from the med tech space as well.

Access the full-text article here.